Poonawalla Aviation Pvt. Ltd. (PAPL) is a Pune based non scheduled operator incorporated under the Poonawalla Group of companies, currently managing one of India’s youngest charter fleets with an average age of less than 3 years.

Founded in 2005, Poonawalla Aviation strives to offer its clients a bespoke charter experience on a carefully curated fleet, solidifying our commitment to luxury and exceptional service, in accordance with the highest standards of safety.

Luxury car pick ups, connecting helicopter flights, dietary preferences & restrictions, seamless airport transfers and much more can be organised by us to compliment your dynamic travel plans.

Poonawalla Aviation is currently working towards getting ARGUS and WYVERN rated to highlight our commitment towards following internationally accepted best practices for safety.

Poonawalla Aviation Pvt. Ltd. (PAPL) is a Pune based non scheduled operator incorporated under the Poonawalla Group of companies, currently managing one of India’s youngest charter fleets with an average age of less than 3 years.

Founded in 2005, Poonawalla Aviation strives to offer its clients a bespoke charter experience on a carefully curated fleet, solidifying our commitment to luxury and exceptional service, in accordance with the highest standards of safety.

Luxury car pick ups, connecting helicopter flights, dietary preferences & restrictions, seamless airport transfers and much more can be organised by us to compliment your dynamic travel plans.

Poonawalla Aviation is currently working towards getting ARGUS and WYVERN rated to highlight our commitment towards following internationally accepted best practices for safety.

Dr. Cyrus Poonawalla, Chairman of Poonawalla Group which includes the privately owned Serum Institute of India, India’s top biotech company and the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses).

In 1966 Dr. Poonawalla founded Serum Institute of India (SII) which launched its first therapeutic anti-tetanus serum within two years, and began producing the anti-tetanus vaccines.

By 1974 Serum Institute introduced the DTP vaccine, which protects children from diphtheria, tetanus and pertussis, followed by an anti-snake-venom serum for snakebites in 1981.

In 1989 Serum Institute began the production of its Measles Vaccine M-Vac and within a year Serum Institute became the country’s largest vaccine manufacturer. In the 80s India was made self-sufficient for Tetanus, Diphtheria and Whooping Cough vaccines thanks to the production from Serum Institute.

In 1994, Serum Institute got accredited by the World Health Organization (WHO) to export vaccines from India and started supplying high quality vaccines to U.N. Agencies such as UNICEF (United Nations Children’s Fund), PAHO (Pan American Health Organization).

From the inception, Dr. Poonawalla’s primary concept was not only to make life-saving drugs and vaccines, which were in shortage in the country, but also to see that every child was protected. At that time his dictum was “Health for all by 2000 AD”. The resultant effort was the National Program of Immunization, which is largely dependent on the vaccines manufactured by Serum Institute and now that philosophy has proliferated worldwide to International U.N. Agencies.

By 1998 Serum Institute was exporting vaccines to over a 100 countries and by 2000 one out of every two children in the world was vaccinated by a vaccine of Serum Institute of India.

Dr. Poonawalla’s strong belief in “No Compromise with Quality” and willful commitment in “Health for All with affordable Vaccines” has today lead Serum Institute to become India’s leading biotech company and has now clearly emerged as the world’s largest vaccine manufacturer by number of doses produced and sold (more than 1.3 billion doses) which includes Polio vaccine.

Adar Poonawalla (born 14 January 1981) is the chief executive officer (CEO) and Executive Director of Serum Institute of India. Founded in 1966 by his father, Dr. Cyrus Poonawalla, it is as of 2017 the world’s largest vaccine manufacturer by number of doses produced.

Adar Poonawalla joined Serum Institute in 2001 after graduating from the University of Westminster in London. Then exporting its products to 35 countries, Poonawalla concentrated on the company’s international market and getting new products licensed and pre-qualified by the World Health Organization for supply to United Nations Agencies including UNICEF and PAHO. As of 2015, the company now exports its products to over 140 countries. 85 percent of its revenues are from overseas.

In 2011 he became the CEO of Serum Institute of India with full control of day-to-day operations of the company. In 2012 he played a major role in the acquisition of Bilthoven Biologicals, a Netherlands-based government vaccine manufacturing company. Poonawalla is a board member of the GAVI Alliance, the global Vaccine Alliance.

He initiated and launched Serum Institute’s Oral Polio Vaccine in 2014, which addressed a global shortage of Polio vaccine at the time and every year plans to launch a new vaccines for public health starting from 2017. In 2014, it was reported that he planned to expand the product portfolio to include vaccines for dengue, flu and cervical cancer.

He is the recipient of many business and philanthropy awards from CNBC TV18, CNN TV18, Economic Times, Hurun and many others to name a few in the recent past.

In 2013 he hosted Charles, Prince of Wales and The Duchess of Cornwall during a private visit to Serum Institute’s manufacturing facility in India.

He was also listed by GQ magazine as one of the 50 most influential young Indians and also was awarded Philanthropist of the year 2016.

In 2011, he found the Villoo Poonawalla Foundation in memory of his late mother which today has 6 schools, 1 hospital, 25 water plants at different locations, 250 trucks and machines picking up and processing waste in and around the city of Pune. His vision is to help address the inequality that exists in India and the world in the focused areas of healthcare, education, water, sanitation and the environment.

Natasha Poonawalla is an Indian philanthropist, Chairperson of the Villoo Poonawalla Foundation, Executive Director of Serum Institute of India, one of the largest vaccine manufacturing company in the world by number of doses produced, Director of the Poonawalla Science Park in the Netherlands and Director of Villoo Poonawalla Racing and Breeding Pvt Ltd.

Natasha is well known for her sartorial fashion choices and design endeavours executing several creative projects for the group, she is equally passionate about the business stratergy of the group with a focus on relationship management for the Cyrus Poonawalla group of companies.

Natasha Poonawalla studied in St. Mary’s School and pursued a bachelor’s degree from Pune University. She simultaneously attended summer programs in the United States at Cornell, Stanford and Harvard University. Natasha Poonawalla degree was an MSc from the London School of Economics in Organisational Behaviour.

She is a business and fashion icon but more than that her soul is of a philanthropist. She through her family foundation supports schools, a hospital and a large sanitation program for underprivileged and economically backward sections of the society. She believes that philanthropy and the power to influence is the ultimate luxury.

Dr. Cyrus Poonawalla, Chairman of Poonawalla Group which includes the privately owned Serum Institute of India, India’s top biotech company and the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses).

In 1966 Dr. Poonawalla founded Serum Institute of India (SII) which launched its first therapeutic anti-tetanus serum within two years, and began producing the anti-tetanus vaccines.

By 1974 Serum Institute introduced the DTP vaccine, which protects children from diphtheria, tetanus and pertussis, followed by an anti-snake-venom serum for snakebites in 1981.

In 1989 Serum Institute began the production of its Measles Vaccine M-Vac and within a year Serum Institute became the country’s largest vaccine manufacturer. In the 80s India was made self-sufficient for Tetanus, Diphtheria and Whooping Cough vaccines thanks to the production from Serum Institute.

In 1994, Serum Institute got accredited by the World Health Organization (WHO) to export vaccines from India and started supplying high quality vaccines to U.N. Agencies such as UNICEF (United Nations Children’s Fund), PAHO (Pan American Health Organization).

From the inception, Dr. Poonawalla’s primary concept was not only to make life-saving drugs and vaccines, which were in shortage in the country, but also to see that every child was protected. At that time his dictum was “Health for all by 2000 AD”. The resultant effort was the National Program of Immunization, which is largely dependent on the vaccines manufactured by Serum Institute and now that philosophy has proliferated worldwide to International U.N. Agencies.

By 1998 Serum Institute was exporting vaccines to over a 100 countries and by 2000 one out of every two children in the world was vaccinated by a vaccine of Serum Institute of India.

Dr. Poonawalla’s strong belief in “No Compromise with Quality” and willful commitment in “Health for All with affordable Vaccines” has today lead Serum Institute to become India’s leading biotech company and has now clearly emerged as the world’s largest vaccine manufacturer by number of doses produced and sold (more than 1.3 billion doses) which includes Polio vaccine.

Adar Poonawalla (born 14 January 1981) is the chief executive officer (CEO) and Executive Director of Serum Institute of India. Founded in 1966 by his father, Dr. Cyrus Poonawalla, it is as of 2017 the world’s largest vaccine manufacturer by number of doses produced.

Adar Poonawalla joined Serum Institute in 2001 after graduating from the University of Westminster in London. Then exporting its products to 35 countries, Poonawalla concentrated on the company’s international market and getting new products licensed and pre-qualified by the World Health Organization for supply to United Nations Agencies including UNICEF and PAHO. As of 2015, the company now exports its products to over 140 countries. 85 percent of its revenues are from overseas.

In 2011 he became the CEO of Serum Institute of India with full control of day-to-day operations of the company. In 2012 he played a major role in the acquisition of Bilthoven Biologicals, a Netherlands-based government vaccine manufacturing company. Poonawalla is a board member of the GAVI Alliance, the global Vaccine Alliance.

He initiated and launched Serum Institute’s Oral Polio Vaccine in 2014, which addressed a global shortage of Polio vaccine at the time and every year plans to launch a new vaccines for public health starting from 2017. In 2014, it was reported that he planned to expand the product portfolio to include vaccines for dengue, flu and cervical cancer.

He is the recipient of many business and philanthropy awards from CNBC TV18, CNN TV18, Economic Times, Hurun and many others to name a few in the recent past.

In 2013 he hosted Charles, Prince of Wales and The Duchess of Cornwall during a private visit to Serum Institute’s manufacturing facility in India.

He was also listed by GQ magazine as one of the 50 most influential young Indians and also was awarded Philanthropist of the year 2016.

In 2011, he found the Villoo Poonawalla Foundation in memory of his late mother which today has 6 schools, 1 hospital, 25 water plants at different locations, 250 trucks and machines picking up and processing waste in and around the city of Pune. His vision is to help address the inequality that exists in India and the world in the focused areas of healthcare, education, water, sanitation and the environment.

Natasha Poonawalla is an Indian philanthropist, Chairperson of the Villoo Poonawalla Foundation, Executive Director of Serum Institute of India, one of the largest vaccine manufacturing company in the world by number of doses produced, Director of the Poonawalla Science Park in the Netherlands and Director of Villoo Poonawalla Racing and Breeding Pvt Ltd.

Natasha is well known for her sartorial fashion choices and design endeavours executing several creative projects for the group, she is equally passionate about the business stratergy of the group with a focus on relationship management for the Cyrus Poonawalla group of companies.

Natasha Poonawalla studied in St. Mary’s School and pursued a bachelor’s degree from Pune University. She simultaneously attended summer programs in the United States at Cornell, Stanford and Harvard University. Natasha Poonawalla degree was an MSc from the London School of Economics in Organisational Behaviour.

She is a business and fashion icon but more than that her soul is of a philanthropist. She through her family foundation supports schools, a hospital and a large sanitation program for underprivileged and economically backward sections of the society. She believes that philanthropy and the power to influence is the ultimate luxury.

Poonawalla Aviation Pvt. Ltd. (PAPL) is a Pune based non scheduled operator incorporated under the Poonawalla Group of companies, currently managing one of India’s youngest charter fleets with an average age of less than 3 years.

Founded in 2005, Poonawalla Aviation strives to offer its clients a bespoke charter experience on a carefully curated fleet, solidifying our commitment to luxury and exceptional service, in accordance with the highest standards of safety.

Luxury car pick ups, connecting helicopter flights, dietary preferences & restrictions, seamless airport transfers and much more can be organised by us to compliment your dynamic travel plans.

Poonawalla Aviation is currently working towards getting ARGUS and WYVERN rated to highlight our commitment towards following internationally accepted best practices for safety.